Induced Pluripotent Stem Cell (iPSC) Market Poised for 9.6 % Growth, Set to Hit $5.29 Billion by 2029

Which drivers are expected to have the greatest impact on the over the induced pluripotent stem cell (ipsc) market's growth?
The escalation of chronic illnesses' prevalence serves as a significant factor propelling the induced pluripotent stem cell market's expansion. These long-term ailments, like heart conditions, cancer, stroke, and diabetes, find their treatment in induced pluripotent stem cells. These kinds of cells, derived from any tissue of a child or adult and genetically modified to mimic embryonic stem cells, hold significant medical potential. The Partnership to Fight Chronic Disorder's (PFCD) report revealed that about 45% of the 133 million Americans, had at least one chronic disorder. Furthermore, the estimations showed that chronic diseases constituted about 1.7 million or 7 out of 10 deaths in the United States. These deaths could potentially be managed using induced pluripotent stem cell treatments, thereby driving up the demand for the induced pluripotent stem cell treatment market due to the rising occurrence of chronic diseases.

Get Your Induced Pluripotent Stem Cell (iPSC) Market Report Here:
https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

What is the future CAGR of the induced pluripotent stem cell (ipsc) market, and how will it impact industry expansion?
In recent years, the market size for induced pluripotent stem cell (iPSC) has experienced a significant expansion. The growth is expected to continue, seeing an increase from $3.3 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth observed in the historical period can be linked to factors such as increased expenditure in healthcare, constant rise in funding, an enhanced understanding of the medicinal benefits of stem cell products, the application of induced pluripotent stem cell (IPSC) in drug discovery, the growing demand for personalized medicine, and the cost effectiveness of IPSC in drug discovery.

The market for induced pluripotent stem cells (iPSC) is anticipated to experience robust expansion in the coming years. It is projected to reach a value of $5.29 billion in 2029, escalating at a compound annual growth rate (CAGR) of 9.6%. This surge over the predicted period can be linked to an increased occurrence of chronic ailments, expansion in genomic projects, the creation of IPSC-derived disease prototypes, the rising incidence of hereditary diseases, governmental endeavors, and fast-paced technological advancement. The forecast period is set to witness significant trends including the use of pluripotent stem cells for Parkinson's disease (PD), strategic affiliations and partnerships, the creation of induced pluripotent stem cell IPSC-derived NK cells, and the use of induced pluripotent stem cells (iPSC) in cell therapy. Additionally, there will be an enhancement in investments in regenerative medicine research and development, the formulation of IPSC expansion mediums, customization of IPSC, and utilization of pluripotent stem cells in treating type I diabetes.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2515&type=smp

What trends are poised to drive the future success of the induced pluripotent stem cell (ipsc) market?
Firms in the Induced Pluripotent stem cell market are seeking strategic partnerships and alliances that can enable them to broaden their reach in new regions and diversify their product range. For instance, Bristol Myers Squibb and Century Therapeutics initiated a strategic partnership in January 2022 to engineer IPSC-derived allogenic cell treatments for acute myeloid leukemia and multiple myeloma. Additionally, in May 2022, a strategic alliance was announced between Evotec and Sernova to develop an IPSC-based beta cell replacement therapy for both type 1 and type 2 diabetes.

Which key market segments comprise the induced pluripotent stem cell (ipsc) market and drive its revenue growth?
The induced pluripotent stem cell (iPSC) market covered in this report is segmented -

1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types
2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy
3) By End-User: Hospitals, Research Laboratories

Subsegments:
1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing, Disease Modeling And Regenerative Therapies
2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair, Fibroblast-Based Disease Research
3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research, Skin Regeneration Therapies
4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research, Amniotic Fluid-Based Regenerative Applications
5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling, Cardiomyocytes For Heart Disease Studies, Endothelial Cells For Vascular Research

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2515

What regions are at the forefront of induced pluripotent stem cell (ipsc) market expansion?
North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2024. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (IPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the leading players fueling growth in the induced pluripotent stem cell (ipsc) market?
Major companies operating in the induced pluripotent stem cell (iPSC) market include FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio, Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=2515&type=smp

What Is Covered In The Induced Pluripotent Stem Cell (iPSC) Global Market Report?

• Market Size Forecast: Examine the induced pluripotent stem cell (ipsc) market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the induced pluripotent stem cell (ipsc) market for a structured understanding.
• Key Players Overview: Analyze major players in the induced pluripotent stem cell (ipsc) market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the induced pluripotent stem cell (ipsc) market.
• Segment Contributions: Evaluate how different segments drive overall growth in the induced pluripotent stem cell (ipsc) market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the induced pluripotent stem cell (ipsc) market.
• Industry Challenges: Identify potential risks and obstacles affecting the induced pluripotent stem cell (ipsc) market.
• Competitive Landscape: Review strategic developments in the induced pluripotent stem cell (ipsc) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.